Template for risk assessment: Difference between revisions
(Created page with "{{RiskAssessment |printiple_investigator=tolland }} This is a test risk assessment") |
m (Tolland moved page Test1 to Template for risk assessment without leaving a redirect) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
|printiple_investigator=tolland | |printiple_investigator=tolland | ||
}} | }} | ||
This is a | |||
{|- | |||
|created||17 June 2014 | |||
|- | |||
|updated||17 June 2014 | |||
|- | |||
|approved date||NA | |||
|- | |||
|status||Template | |||
|} | |||
== Description of Project == | |||
Routine cloning and manipulation of harmless eukaryotic sequences in disabled E. coli K12 strains using non-mobilisable and/or mobilisation-defective vectors, with no intention to express gene products. | |||
== Location of Work == | |||
The GM activity with take place in the London Hackspace biolab at 447 Hackney Road, London, E2 9DY | |||
The laboratory work will be done at CL-1 | |||
There will be no animal work | |||
== Principal Investigator == | |||
Tom Hodder | |||
== Other Personnel == | |||
Sam Thompson | |||
== Description of the project, including the methods to be used and the purpose of the genetic modification == | |||
This is a generic risk assessment for cloning harmless sequences from any eukaryotic organism into disabled E. coli K12 hosts for the purpose of facilitating molecular biology procedures such as (i) sub-cloning, DNA sequencing, or site-directed mutagenesis; (ii) construction of fusions with harmless reporter genes such as GFP; (iii) construction of recombinant plasmids for subsequent transfection of eukaryotic cell lines; (iv) construction of recombinant plasmids for subsequent transfection of defined packaging cell lines for the purpose of producing disabled recombinant viral vectors. [Note: in examples (iii) and (iv), the subsequent transfection experiments will need to be covered by separate, specific risk assessments]. | |||
This risk assessment specifically excludes cloning sequences that are known or suspected to: | |||
(i) be oncogenic; | |||
or (ii) encode either a toxin or an allergen; | |||
or (iii) encode a product that could have detrimental effect if delivered to a target tissue. | |||
[Note: cloning any of the above types of excluded sequences will need to be covered by non-generic, specific risk assessments.]. | |||
Latest revision as of 00:21, 17 June 2014
| Principle Investigaor | tolland |
|---|
| created | 17 June 2014 |
| updated | 17 June 2014 |
| approved date | NA |
| status | Template |
Description of Project
Routine cloning and manipulation of harmless eukaryotic sequences in disabled E. coli K12 strains using non-mobilisable and/or mobilisation-defective vectors, with no intention to express gene products.
Location of Work
The GM activity with take place in the London Hackspace biolab at 447 Hackney Road, London, E2 9DY
The laboratory work will be done at CL-1
There will be no animal work
Principal Investigator
Tom Hodder
Other Personnel
Sam Thompson
Description of the project, including the methods to be used and the purpose of the genetic modification
This is a generic risk assessment for cloning harmless sequences from any eukaryotic organism into disabled E. coli K12 hosts for the purpose of facilitating molecular biology procedures such as (i) sub-cloning, DNA sequencing, or site-directed mutagenesis; (ii) construction of fusions with harmless reporter genes such as GFP; (iii) construction of recombinant plasmids for subsequent transfection of eukaryotic cell lines; (iv) construction of recombinant plasmids for subsequent transfection of defined packaging cell lines for the purpose of producing disabled recombinant viral vectors. [Note: in examples (iii) and (iv), the subsequent transfection experiments will need to be covered by separate, specific risk assessments].
This risk assessment specifically excludes cloning sequences that are known or suspected to: (i) be oncogenic;
or (ii) encode either a toxin or an allergen; or (iii) encode a product that could have detrimental effect if delivered to a target tissue.
[Note: cloning any of the above types of excluded sequences will need to be covered by non-generic, specific risk assessments.].
